DOCSLIB.ORG

List of Section 13F Securities, First Quarter, 2009

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

List of Section 13F Securities 1st Quarter FY 2009 Copyright (c) 2009 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of March 15, 2009, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending March 31, 2009. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled “STATUS.” The word “ADDED” in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word “DELETED” in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form13F should use the CUSIP number of the underlying securities to which the option relates. CUSIP descriptions and numerical identification date (copyright 1969 through 2009, American Bankers Association) are used with permission. All rights are reserved. Run Date: 3/30/2009 ** List of Section 13F Securities ** Page 1 Run Time: 14:43 Fiscal Year: 2009 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS D1668R 12 3 * DAIMLER AG REG SHS D1668R 90 3 DAIMLER AG CALL D1668R 95 3 DAIMLER AG PUT D18190 89 8 * DEUTSCHE BANK AG NAMEN AKT D18190 90 8 DEUTSCHE BANK AG CALL D18190 95 8 DEUTSCHE BANK AG PUT E90215 10 9 TELVENT GIT SA SHS G0129K 10 4 * AIRCASTLE LTD COM G0129K 90 4 AIRCASTLE LTD CALL G0129K 95 4 AIRCASTLE LTD PUT G0219G 20 3 * ALLIED WRLD ASSUR COM HLDG L SHS G0219G 90 3 ALLIED WRLD ASSUR COM HLDG L CALL G0219G 95 3 ALLIED WRLD ASSUR COM HLDG L PUT G02602 10 3 * AMDOCS LTD ORD G02602 90 3 AMDOCS LTD CALL G02602 95 3 AMDOCS LTD PUT G02995 10 1 AMERICAN SAFETY INS HLDGS LT ORD G04074 10 3 * APEX SILVER MINES LTD ORD DELETED G04074 90 3 APEX SILVER MINES LTD CALL DELETED G04074 95 3 APEX SILVER MINES LTD PUT DELETED G04136 10 0 * A POWER ENERGY GENERAT SYS L COM G04136 90 0 A POWER ENERGY GENERAT SYS L CALL G04136 95 0 A POWER ENERGY GENERAT SYS L PUT G0450A 10 5 * ARCH CAP GROUP LTD ORD G0450A 90 5 ARCH CAP GROUP LTD CALL G0450A 95 5 ARCH CAP GROUP LTD PUT G0464B 10 7 * ARGO GROUP INTL HLDGS LTD COM G0464B 90 7 ARGO GROUP INTL HLDGS LTD CALL G0464B 95 7 ARGO GROUP INTL HLDGS LTD PUT G0474B 10 5 ARIES MARITIME TRNSPRT LTD SHS G04899 10 3 ARLINGTON TANKERS LTD COM DELETED G0538M 10 5 ASIA SPECIAL SIT ACQST CORP SHS G0538M 11 3 ASIA SPECIAL SIT ACQST CORP UNIT 99/99/9999 G05384 10 5 * ASPEN INSURANCE HOLDINGS LTD SHS Run Date: 3/30/2009 ** List of Section 13F Securities ** Page 2 Run Time: 14:43 Fiscal Year: 2009 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G05384 90 5 ASPEN INSURANCE HOLDINGS LTD CALL G05384 95 5 ASPEN INSURANCE HOLDINGS LTD PUT G05384 11 3 ASPEN INSURANCE HOLDINGS LTD PFD PRP INC EQ G0585R 10 6 * ASSURED GUARANTY LTD COM G0585R 90 6 ASSURED GUARANTY LTD CALL G0585R 95 6 ASSURED GUARANTY LTD PUT G0692U 10 9 * AXIS CAPITAL HOLDINGS SHS G0692U 90 9 AXIS CAPITAL HOLDINGS CALL G0692U 95 9 AXIS CAPITAL HOLDINGS PUT G10082 10 8 ENERGY XXI (BERMUDA) LTD COM SHS G1150G 11 1 * ACCENTURE LTD BERMUDA CL A G1150G 90 1 ACCENTURE LTD BERMUDA CALL G1150G 95 1 ACCENTURE LTD BERMUDA PUT G16252 10 1 * BROOKFIELD INFRAST PARTNERS LP INT UNIT G16252 90 1 BROOKFIELD INFRAST PARTNERS CALL G16252 95 1 BROOKFIELD INFRAST PARTNERS PUT G16962 10 5 * BUNGE LIMITED COM G16962 90 5 BUNGE LIMITED CALL G16962 95 5 BUNGE LIMITED PUT G19522 11 2 CASTLEPOINT HOLDINGS LTD COM DELETED G20045 20 2 * CENTRAL EUROPEAN MEDIA ENTRP CL A NEW G20045 90 2 CENTRAL EUROPEAN MEDIA ENTRP CALL G20045 95 2 CENTRAL EUROPEAN MEDIA ENTRP PUT G2022L 10 6 * CDC CORP SHS A G2022L 90 6 CDC CORP CALL G2022L 95 6 CDC CORP PUT G21082 10 5 * CHINA YUCHAI INTL LTD COM G21082 90 5 CHINA YUCHAI INTL LTD CALL G21082 95 5 CHINA YUCHAI INTL LTD PUT G2110R 10 6 * CHIPMOS TECH BERMUDA LTD SHS G2110R 90 6 CHIPMOS TECH BERMUDA LTD CALL G2110R 95 6 CHIPMOS TECH BERMUDA LTD PUT G2110U 10 9 CHINA NATURAL RESOURCES INC COM G21176 10 5 CHINA CABLECOM HOLDINGS LTD SHS Run Date: 3/30/2009 ** List of Section 13F Securities ** Page 3 Run Time: 14:43 Fiscal Year: 2009 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G21176 11 3 CHINA CABLECOM HOLDINGS LTD *W EXP 04/10/201 G21176 20 4 CHINA CABLECOM HOLDINGS LTD UNIT 04/10/2010 G23773 10 7 CONSOLIDATED WATER CO INC ORD G24182 10 0 * COOPER INDS LTD CL A G24182 90 0 COOPER INDS LTD CALL G24182 95 0 COOPER INDS LTD PUT G2519Y 10 8 * CREDICORP LTD COM G2519Y 90 8 CREDICORP LTD CALL G2519Y 95 8 CREDICORP LTD PUT G25343 10 7 * COSAN LTD SHS A G25343 90 7 COSAN LTD CALL G25343 95 7 COSAN LTD PUT G2552X 10 8 * COVIDIEN LTD COM G2552X 90 8 COVIDIEN LTD CALL G2552X 95 8 COVIDIEN LTD PUT G2554P 10 3 CRM HOLDINGS LTD COM G29438 10 1 E FUTURE INFORMATION TECH IN SHS G30397 10 6 * ENDURANCE SPECIALTY HLDGS LT SHS G30397 90 6 ENDURANCE SPECIALTY HLDGS LT CALL G30397 95 6 ENDURANCE SPECIALTY HLDGS LT PUT G3075P 10 1 ENSTAR GROUP LIMITED SHS G3156P 10 3 * ASA LIMITED COM G3156P 90 3 ASA LIMITED CALL G3156P 95 3 ASA LIMITED PUT G3159C 10 9 * CRYPTOLOGIC LIMITED SHS G3159C 90 9 CRYPTOLOGIC LIMITED CALL G3159C 95 9 CRYPTOLOGIC LIMITED PUT G32030 10 1 EURO TECH HOLDINGS CO LTD ORD G3223R 10 8 * EVEREST RE GROUP LTD COM G3223R 90 8 EVEREST RE GROUP LTD CALL G3223R 95 8 EVEREST RE GROUP LTD PUT G3396L 10 2 FGX INTERNATIONAL HLDGS LTD ORD SHS G3529T 10 5 FLAGSTONE REINSURANCE HLDGS SHS G36535 12 1 FOSTER WHEELER LTD *W EXP 09/24/200 DELETED Run Date: 3/30/2009 ** List of Section 13F Securities ** Page 4 Run Time: 14:43 Fiscal Year: 2009 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G36535 13 9 * FOSTER WHEELER LTD SHS NEW DELETED G36535 90 9 FOSTER WHEELER LTD CALL DELETED G36535 95 9 FOSTER WHEELER LTD PUT DELETED G36738 10 5 * FRESH DEL MONTE PRODUCE INC ORD G36738 90 5 FRESH DEL MONTE PRODUCE INC CALL G36738 95 5 FRESH DEL MONTE PRODUCE INC PUT G3682E 12 7 * FRONTLINE LTD SHS G3682E 90 7 FRONTLINE LTD CALL G3682E 95 7 FRONTLINE LTD PUT G3704F 10 2 FUWEI FILMS HLDGS CO LTD SHS G37260 10 9 * GARMIN LTD ORD G37260 90 9 GARMIN LTD CALL G37260 95 9 GARMIN LTD PUT G3921A 17 5 * GLOBAL CROSSING LTD SHS NEW G3921A 90 5 GLOBAL CROSSING LTD CALL G3921A 95 5 GLOBAL CROSSING LTD PUT G3922B 10 7 * GENPACT LIMITED SHS G3922B 90 7 GENPACT LIMITED CALL G3922B 95 7 GENPACT LIMITED PUT G39300 10 1 GLOBAL SOURCES LTD ORD G39320 11 7 GLOBAL TECH ADVANCED INNOVAT SHS NEW G4095J 10 9 * GREENLIGHT CAPITAL RE LTD CLASS A G4095J 90 9 GREENLIGHT CAPITAL RE LTD CALL G4095J 95 9 GREENLIGHT CAPITAL RE LTD PUT G4388N 10 6 * HELEN OF TROY CORP LTD COM G4388N 90 6 HELEN OF TROY CORP LTD CALL G4388N 95 6 HELEN OF TROY CORP LTD PUT G4412G 10 1 * HERBALIFE LTD COM USD SHS G4412G 90 1 HERBALIFE LTD CALL G4412G 95 1 HERBALIFE LTD PUT G4481U 10 6 HIGHWAY HLDGS LTD ORD G4604M 10 6 HLS SYSTEMS INTERNATIONAL LT USD COM G4776G 10 1 * INGERSOLL-RAND COMPANY LTD CL A G4776G 90 1 INGERSOLL-RAND COMPANY LTD CALL Run Date: 3/30/2009 ** List of Section 13F Securities ** Page 5 Run Time: 14:43 Fiscal Year: 2009 Qtr: 1 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G4776G 95 1 INGERSOLL-RAND COMPANY LTD PUT G491BT 10 8 * INVESCO LTD SHS G491BT 90 8 INVESCO LTD CALL G491BT 95 8 INVESCO LTD PUT G4933P 10 1 * IPC HLDGS LTD ORD G4933P 90 1 IPC HLDGS LTD CALL G4933P 95 1 IPC HLDGS LTD PUT G5138L 10 0 JINPAN INTL LTD ORD G5299G 10 6 * KNIGHTSBRIDGE TANKERS LTD ORD G5299G 90 6 KNIGHTSBRIDGE TANKERS LTD CALL G5299G 95 6 KNIGHTSBRIDGE TANKERS LTD PUT G54050 10 2 * LAZARD LTD SHS A G54050 90 2 LAZARD LTD CALL G54050 95 2 LAZARD LTD PUT G55312 10 5 * LJ INTL INC ORD G55312 90 5 LJ INTL INC CALL G55312 95 5 LJ INTL INC PUT G5753U 11 2 MAIDEN HOLDINGS LTD SHS G5876H 10 5 * MARVELL TECHNOLOGY GROUP LTD ORD G5876H 90 5 MARVELL TECHNOLOGY GROUP LTD CALL G5876H 95 5 MARVELL TECHNOLOGY GROUP LTD PUT G6052F 10 3 * MAX CAPITAL GROUP LTD SHS G6052F 90 3 MAX CAPITAL GROUP LTD CALL G6052F 95 3 MAX CAPITAL GROUP LTD PUT G60642 10 8 * MF GLOBAL LTD SHS G60642
Recommended publications
  • Biomarin Pharmaceutical Inc

    Biomarin Pharmaceutical Inc

    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 03/02/15 for the Period Ending 12/31/14 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
  • Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them

    Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them

    2nd Edition Reducing Prescription Drug Costs in Colorado Cost Drivers and Strategies to Address Them January 2021 Contents Forward to Reducing Prescription Drug Costs in Colorado, 2nd Edition ........... 4 2020 Updates to This Report .................................................................. 4 Executive Summary ............................................................................ 6 Introduction and Purpose ...................................................................... 6 Cost Drivers ...................................................................................... 7 Prioritized Solutions ............................................................................ 8 Learning from Medicaid Policy ............................................................... 12 The Department Invites Your Collaborative Partnership .................................. 12 Industry Trends and Background Information ............................................. 13 Prescription Drug Cost, Utilization, and Trends ........................................... 13 The U.S. Pays the Highest Prices for Pharmaceutical Drugs in the World .............. 16 Many Coloradans Aren’t Taking Their Drugs Appropriately Because They Can’t Afford Them, Often Leading to Worse Health Outcomes That Are More Costly ....... 16 Major Drivers of Prescription Drug Prices .................................................. 18 Patent Protections .............................................................................. 18 Anti-Competitive Practices and Price Fixing
  • Amifampridine Phosphate (Firdapse®)

    Amifampridine Phosphate (Firdapse®)

    AMIFAMPRIDINE PHOSPHATE (FIRDAPSEVR ) IS EFFECTIVE AND SAFE IN A PHASE 3 CLINICAL TRIAL IN LEMS SHIN J OH, MD,1 NATALYA SHCHERBAKOVA, MD,2 ANNA KOSTERA-PRUSZCZYK, MD, PhD,3 MOHAMMAD ALSHARABATI, MD,1 MAZEN DIMACHKIE, MD,4 JOSE MUNOZ BLANCO, MD,5 THOMAS BRANNAGAN, MD,6 DRAGANA LAVRNIC´ , MD, PhD,7 PERRY B SHIEH, MD, PhD,8 CHRISTOPHE VIAL, MD,9 ANDREAS MEISEL, MD,10 SAMUEL KOMOLY, MD, PhD, DSc,11 BENEDIKT SCHOSER, MD,12 KUMARASWAMY SIVAKUMAR, MD,13 YUEN SO, MD, PhD,14 and LEMS STUDY GROUP 1 Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA 2 Russian Academy of Medical Sciences, Scientific Center of Neurology, Moscow, Russia 3 Department of Neurology, Medical University of Warsaw, Poland 4 University of Kansas Medical Center, Kansas City, Kansas, USA 5 Gregorio Maranon Hospital, Madrid, Spain 6 Columbia University Medical Center, New York, New York, USA 7 Clinical Center of Serbia, Clinic of Neurology, Belgrade, Serbia 8 Department of Neurology, University of California, Los Angeles, California, USA 9 Hospital of Lyon, ENMG Service and Neuromuscular Pathology Hospital, Lyon, France 10 Charite Universitatsmedizin Berlin-NeuroCure Clinical Research Center, Berlin, Germany 11 University of Pecs, Department of Neurology, Pecs, Hungary 12 Ludwig-Maximilians-University Munich Friedrich-Baur-Institute, Munich, Germany 13 Neuromuscular Research Center, Phoenix, Arizona, USA [email protected] 14 Stanford University, Stanford, California, USA Accepted 4 February 2016 ABSTRACT: Objective: We evaluated the efficacy and safety ated; the most common adverse events were oral and digital of amifampridine phosphate (FirdapseVR ) for symptomatic treat- paresthesias, nausea, and headache. Conclusions: This study ment in Lambert-Eaton myasthenic syndrome (LEMS).
  • 2019 Or ☐ TRANSITION REPORT PURSUANT to SECTION 13 OR 15(D) of the SECURITIES EXCHANGE ACT of 1934

    2019 Or ☐ TRANSITION REPORT PURSUANT to SECTION 13 OR 15(D) of the SECURITIES EXCHANGE ACT of 1934

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) ____________ Delaware 68-0397820 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael California 94901 (Address of principal executive offices) (Zip Code) (415) 506-6700 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 BMRN The Nasdaq Global Select Market Securities registered under Section 12(g) of the Act: None ____________ Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • Health Care Opportunities Portfolio // Portfolio Selected By: Peroni Portfolio Advisors, Inc

    Health Care Opportunities Portfolio // Portfolio Selected By: Peroni Portfolio Advisors, Inc

    EQUITY - SECTOR / INDUSTRY FOCUS Series 2020-2, ADT 2019 Health Care Opportunities Portfolio // Portfolio Selected by: Peroni Portfolio Advisors, Inc. Morningstar Equity Style BoxTM Investment Objective & Strategy The Health Care Opportunities Portfolio, a unit investment trust (UIT), seeks to provide capital appreciation by investing in a portfolio of common stocks of companies involved in various areas of the health care sector including biotechnology, life sciences, medical equipment/technology, health care providers and pharmaceuticals. The portfolio was selected by Eugene E. Peroni, Jr. of Peroni Portfolio Advisors, Inc., the Portfolio Consultant, through the application of his proprietary method of technical analysis, the Peroni Method®, with consideration of investment opportunities under the health care theme. Ticketing Information CUSIP (Cash/Reinvest) 00780M743 / 750 Health Care Today Fee-Based CUSIP (Cash/Reinvest) 00780M768 / 776 MSWM Cash AHCP202 The United States Census Bureau projects a rapid increase in the elderly population over the next several decades and beyond. Baby boomers are the single largest generation in American history Essential Information and this generation may require massive amounts of health care in the near future. Globally, Unit price at inception (per unit) $10.000 people are living longer than they used to due to advances in health care technology, treatments Initial redemption price (per unit) $9.7750 and services. In this regard, the Health Care Opportunities Portfolio includes stocks in a number of Initial date of deposit 6/11/2020 industries involved in the many facets of health care that should be considered long term when Portfolio ending date 6/8/2022 investing in this diverse sector.
  • To Download the Full Report, Click Here

    To Download the Full Report, Click Here

    STRENGTHENING BIOPHARMACEUTICAL Ohio BOLD:INNOVATION: A Blueprint forTHE Accelerating GROWING ROLE OF the InnovationCORPORATE Economy VENTURE CAPITAL Performed For: Ohio Chamber of Commerce Research Foundation OCTOBER 2018 Performed By: TEConomy Partners, LLC JULY 2018 Prepared for: Prepared by: TEConomy Partners, LLC (TEConomy) endeavors at all times to produce work of the highest quality, consistent with our contract commitments. However, because of the research and/or experimental nature of this work, the client under- takes the sole responsibility for the consequence of any use or misuse of, or inability to use, any information or result obtained from TEConomy, and TEConomy, its partners, or employees have no legal liability for the accuracy, adequa- cy, or efficacy thereof. TABLE OF CONTENTS Executive Summary i Introduction: Corporate Venture Capital Comes of Age 1 The Rise and Transformation of Corporate Venture Capital ...............................1 Innovation-based Biopharmaceutical Companies Are Leaders in CVC Investment.................................................................................4 Setting the Context: Growing PhRMA-member CVC activity comes at a time of unprecedented opportunity but rising challenges for medical innovation .................................................................................................6 Key Trends and Contributions of CVC Activity by Biopharmaceutical Companies 9 Biopharmaceutical CVCs are now a significant share of overall biopharmaceutical investment .............................................................10
  • Annual Report 2

    Annual Report 2

    Draft as of December 20. PDF version for illustrative purposes, report will be published online. ANNUAL REPORT 2 Key Figures for 2019 MERCK GROUP Key figures Change € million 2019 2018 € million % Net sales 16,152 14,836 1,315 8.9% Operating result (EBIT)1 2,120 1,727 393 22.8% Margin (% of net sales)1 13.1% 11.6% EBITDA1 4,066 3,528 539 15.3% Margin (% of net sales)1 25.2% 23.8% EBITDA pre1 4,385 3,800 585 15.4% Margin (% of net sales)1 27.1% 25.6% Profit after tax 1,324 3,396 -2,072 -61.0% Earnings per share (in €) 3.04 7.76 -4.72 -60.8% Earnings per share pre (€)1 5.56 5.10 0.46 9.0% Business free cash flow1 2,732 2,508 224 8.9% 1Not defined by International Financial Reporting Standards (IFRSs). MERCK GROUP MERCK GROUP Net sales EBITDA pre1 € million € million 1 Not defined y International Financial Reporting Standards (IFRSs). Owing to the altered expectations in terms of the impact of the Covid-19 pandemic, some chapters of this Annual Report were updated on May 12, 2020. The respective text passages are marked in magenta. Table of Contents Annual Report To Our Shareholders Corporate Governance 5 Letter from Stefan Oschmann 136 Capital Structure and Corporate Bodies of Merck KGaA 8 The Executive Board 137 Statement on Corporate Governance including Compensation Report 9 Merck Shares 167 Report of the Supervisory Board 170 Objectives of the Supervisory Board with respect to Its Composition and Profile of Skills and Expertise Combined Consolidated Management Report Financial Statements 12 Fundamental Information about the 174 Consolidated
  • 2019 Annual Report

    2019 Annual Report

    2019 ANNUAL REPORT Dear Shareholders, I am pleased to report that 2019 was a very positive and transformational year for Catalyst and, most importantly, for the patients that we seek to help. The year was purpose-driven, as we transformed to a fully integrated commercial-stage biopharmaceutical company with the successful launch of Firdapse® for adult patients suffering from Lambert-Eaton Myasthenic Syndrome (LEMS). We are gratified with the positive response that we have received from the LEMS community of patients and healthcare providers since our launch of Firdapse® in January 2019. We believe that it was extremely important to go through the rigors required to get Firdapse® approved by the FDA, so that all adult LEMS patients, and not just a select few who participated in an early access program, would have affordable access to an FDA approved therapy to treat their rare disease. Of all that we accomplished in 2019 and during the first half of 2020, I am proud that because of the efforts of the Catalyst team, Firdapse® has become the market leader and standard of care for the treatment of adult LEMS patients. I am most excited by the growth and progress that our company has made across all functional areas of our business, including the financial results that we reported for our first year as a commercial company. When we launched Firdapse® (amifampridine) 10 mg tablets in the U.S. for adult LEMS patients, we identified key objectives for the year based upon-patient enrollments in Catalyst Pathways, physician adoption rates for Firdapse®, and high patient satisfaction ratings.
  • Investor Relations : Biomarin

    Investor Relations : Biomarin

    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 02/26/13 for the Period Ending 12/31/12 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68 -0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
  • Investor Relations : Biomarin

    Investor Relations : Biomarin

    BIOMARIN PHARMACEUTICAL INC FORM 10-K (Annual Report) Filed 02/29/16 for the Period Ending 12/31/15 Address 105 DIGITAL DRIVE NOVATO, CA 94949 Telephone 4155066700 CIK 0001048477 Symbol BMRN SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2016, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. ff UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) Delaware 68-0397820 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 770 Lindaro Street San Rafael, California 94901 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (415) 506-6700 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $.001 par value The NASDAQ Global Select Market Securities registered under Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
  • ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do

    ANNUAL REPORT 2018 … Is at the Heart of Every- Thing We Do

    Science ANNUAL REPORT 2018 … is at the heart of every- thing we do. € 2.2 BILLION invested in research and development in 2018. Around 52,000 hearts at Merck beat for science. Employees in 66 countries share a passion for pushing boundaries and making new discoveries. Since 1668, the name Merck has stood for the positive power of science. Online You can find out what else makes our research hearts beat faster at www.merckgroup.com/en/ annualreport/2018 “ We believe that scientific exploration and responsible entrepreneurship make techno- logical advantages possible that benefit us all.” STEFAN OSCHMANN Chairman of the Executive Board and CEO Key Figures for 2018 MERCK GROUP Key figures 1 Change € million 2018 2017 € million in % Net sales 14,836 14,517 319 2.2% Operating result (EBIT)2 1,727 2,423 – 696 – 28.7% Margin (% of net sales)2 11.6% 16.7% EBITDA2 3,528 4,164 – 636 – 15.3% Margin (% of net sales)2 23.8% 28.7% EBITDA pre2 3,800 4,246 – 446 – 10.5% Margin (% of net sales)2 25.6% 29.3% Profit after tax 3,396 2,615 781 29.9% Earnings per share (€) 7.76 5.99 1.77 29.5% Earnings per share pre (€)2 5.10 5.92 – 0.82 – 13.9% Business free cash flow2 2,508 3,193 – 685 – 21.4% 1 Fiscal 2017 has been adjusted, see Note (49) “Effects from new accounting standards and other presentation and measurement changes” in the Notes to the Consolidated Financial Statements. 2 Not defined by International Financial Reporting Standard IFRS( s).